La Maddalena S.p.A.

Palermo 13 trials 7 recruiting

13 Registered trials

7 Currently recruiting

Organisation

La Maddalena S.p.A.

Location

Palermo, Italy

Identifier

ORG-100019351

Address

Via San Lorenzo 312d, 90146, Italy

Departments

138011: Emato-Oncologia e TMO
DIPARTIMENTO ONCOLOGICO
Medical Oncology
Oncologia Medica
Oncology
Surgical Oncology
U.O. Oncologia
U.O. Oncologia medica
UO Oncologia Medica

Clinical trials at this site (13)

Search interface

Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Pending

2024-518386-95-02 Non small-cell lung cancer 4
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) s… Recruiting

2024-518223-29-00 Advanced or metastatic untreated EGFR mutation positive 4 2020-03-10
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting

2023-509142-35-00 Atrial fibrillation after stress (e.g., noncardiac surg 6 2024-01-29
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Advanced non-small-cell lung cancer 4 2020-01-31
Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended

2024-512180-31-00 Oligometastatic renal cell carcinoma 4 2025-03-14
An open-label, single-arm, Phase II, multinational, multicentre study to assess the efficacy and safety of 5 years of osimertinib in partici… Ended

2023-508740-21-00 Non-Small Cell Lung Cancer 4 2023-02-15
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung… Ended

2024-513770-22-00 Malignant Solid Tumors - Non Small Cell Lung Cancer 4 2021-09-22
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01